<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6222329</article-id><article-id pub-id-type="doi">10.3390/molecules23082033</article-id><article-id pub-id-type="publisher-id">molecules-23-02033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer&#8217;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hussein</surname><given-names>Weiam</given-names></name><xref ref-type="aff" rid="af1-molecules-23-02033">1</xref><xref ref-type="aff" rid="af2-molecules-23-02033">2</xref></contrib><contrib contrib-type="author"><name><surname>Sa&#287;l&#305;k</surname><given-names>Beg&#252;m Nurpelin</given-names></name><xref ref-type="aff" rid="af2-molecules-23-02033">2</xref><xref ref-type="aff" rid="af3-molecules-23-02033">3</xref></contrib><contrib contrib-type="author"><name><surname>Levent</surname><given-names>Serkan</given-names></name><xref ref-type="aff" rid="af2-molecules-23-02033">2</xref><xref ref-type="aff" rid="af3-molecules-23-02033">3</xref></contrib><contrib contrib-type="author"><name><surname>Korkut</surname><given-names>B&#252;&#351;ra</given-names></name><xref ref-type="aff" rid="af4-molecules-23-02033">4</xref></contrib><contrib contrib-type="author"><name><surname>Ilg&#305;n</surname><given-names>Sinem</given-names></name><xref ref-type="aff" rid="af4-molecules-23-02033">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8815-153X</contrib-id><name><surname>&#214;zkay</surname><given-names>Yusuf</given-names></name><xref ref-type="aff" rid="af2-molecules-23-02033">2</xref><xref ref-type="aff" rid="af3-molecules-23-02033">3</xref><xref rid="c1-molecules-23-02033" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2252-0923</contrib-id><name><surname>Kaplanc&#305;kl&#305;</surname><given-names>Zafer As&#305;m</given-names></name><xref ref-type="aff" rid="af2-molecules-23-02033">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Nekkar Rao</surname><given-names>Praveen P.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-23-02033"><label>1</label>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Aden University, 6075 Aden, Yemen; <email>white.wf.rose@gmail.com</email></aff><aff id="af2-molecules-23-02033"><label>2</label>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eski&#351;ehir, Turkey; <email>bnsaglik@anadolu.edu.tr</email> (B.N.S.); <email>serkanlevent@anadolu.edu.tr</email> (S.L.); <email>zakaplan@anadolu.edu.tr</email> (Z.A.K.)</aff><aff id="af3-molecules-23-02033"><label>3</label>Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, 26470 Eski&#351;ehir, Turkey</aff><aff id="af4-molecules-23-02033"><label>4</label>Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu University, 26470 Eski&#351;ehir, Turkey; <email>busrakorkut@anadolu.edu.tr</email> (B.K.); <email>silgin@anadolu.edu.tr</email> (S.I.)</aff><author-notes><corresp id="c1-molecules-23-02033"><label>*</label>Correspondence: <email>yozkay@anadolu.edu.tr</email>; Tel.: +90-222-335-0580 (ext. 3779)</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2018</year></pub-date><volume>23</volume><issue>8</issue><elocation-id>2033</elocation-id><history><date date-type="received"><day>29</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#169; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Alzheimer&#8217;s disease (AD) is a neurodegenerative disorder mostly influencing the elderly, and causes death due to dementia. The main pathogenic feature connected with the progression of this multifactorial disease is the weakening of the cholinergic system in the brain. Cholinesterase (ChE) inhibitors are recognized as one of the choices in the treatment of AD. The inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) were approved as a therapeutic strategy to reduce the symptoms of AD and prevent its progression. The capacity of BChE is not completely known yet; rather, it is accepted to assume a part in a few disorders such as AD. Thus, BChE inhibitors may have a greater role for the treatment of AD in the future. In the present study, 2-(9-acridinylamino)-2-oxoethyl piperazine/piperidine/morpholinecarbodithioate derivatives were synthesized in order to investigate anticholinesterase activity. Eight derivatives demonstrated a specific and promising action against BChE. Furthermore, compound <bold>4n</bold> showed inhibitory activity against both enzymes. It was found that the active compounds were well tolerated in the cytotoxicity test. Possible interactions between the lead compound, <bold>4n</bold>, and the BChE enzyme were determined through a docking study. The findings obtained within this paper will contribute to the development of new and effective synthetic anti-Alzheimer compounds, and will ideally encourage future screening against AD.</p></abstract><kwd-group><kwd>Alzheimer&#8217;s disease</kwd><kwd>acetylcholinesterase</kwd><kwd>butyrylcholinesterase</kwd><kwd>9-aminoacridine</kwd><kwd>dithiocarbamate salts</kwd><kwd>docking study</kwd></kwd-group></article-meta></front><body><sec id="sec1-molecules-23-02033"><title>1. Introduction</title><p>Alzheimer&#8217;s disease (AD) is a neurological disorder and is one of the most common causes of dementia in the age group above 60 years, for which there is no radical cure. It is estimated from the world population that more than 35.6 million people are currently living with AD, and this may increase to 65.7 million by 2030, and 115.4 million by 2050 [<xref rid="B1-molecules-23-02033" ref-type="bibr">1</xref>]. According to a World Health Organization (WHO) report, more than 50% of people with AD live in the developing world, and it is estimated that this population will be 70% by 2025 [<xref rid="B2-molecules-23-02033" ref-type="bibr">2</xref>]. To date, some cases of low levels of acetylcholine (ACh), oxidative anxiety, dyshomeostasis of biometals, and amyloid-&#946; (A&#946;) stores were exhibited to be related to AD pathogenesis [<xref rid="B3-molecules-23-02033" ref-type="bibr">3</xref>]. In light of these findings, a few speculations were proposed to clarify the progress of AD. The most recognized theory includes the loss of cholinergic neurons in the cerebrum of patients with AD, and a reduced action of choline acetyltransferase, which catalyzes the generation of ACh. Thus, cognitive dysfunction occurs and neurotransmission levels decrease [<xref rid="B4-molecules-23-02033" ref-type="bibr">4</xref>]. In AD, although AChE is generally the primary medication target, recent investigations were additionally centered on a scan for BChE inhibitors [<xref rid="B5-molecules-23-02033" ref-type="bibr">5</xref>,<xref rid="B6-molecules-23-02033" ref-type="bibr">6</xref>,<xref rid="B7-molecules-23-02033" ref-type="bibr">7</xref>,<xref rid="B8-molecules-23-02033" ref-type="bibr">8</xref>]. One of the most interesting studies showed that, when BChE progresses toward the formation of A&#946; plaques, its advanced role involves the conversion of &#8220;harmless&#8221; plaques to &#8220;damaging&#8221; plaques [<xref rid="B9-molecules-23-02033" ref-type="bibr">9</xref>]. Scientists additionally discovered a relationship between a less active variant of BChE (Ala539Thr) and a lower inclination toward growing AD [<xref rid="B10-molecules-23-02033" ref-type="bibr">10</xref>]. Therefore, BChE represents a proper imaging target for early diagnosis and treatment of AD. In this way, new remedial approaches are presently in progress, and exploratory medicine surrounding this approach sped up during the recent decade.</p><p>Carbamates are the most generally contemplated class of AChE inhibitors, on which impressive research was performed in connection to AD. Rivastigmine, a dual AChE and BChE inhibitor, is one of the most broadly utilized anticholinesterase agents bearing a carbamate moiety [<xref rid="B11-molecules-23-02033" ref-type="bibr">11</xref>,<xref rid="B12-molecules-23-02033" ref-type="bibr">12</xref>]. Dithiocarbamates have a great deal of interest in the design of new compounds, which can be obtained via the bioisosteric substitution of a carbamate moiety with a dithiocarbamate moiety. They are critical pharmacophores due to their lipophilicity, which is essential for the transport of drugs to the central nervous system (CNS) through the blood&#8211;brain barrier (BBB) [<xref rid="B13-molecules-23-02033" ref-type="bibr">13</xref>,<xref rid="B14-molecules-23-02033" ref-type="bibr">14</xref>]. Tacrine and donepezil are other anticholinesterase agents that selectively inhibit BChE and AChE, respectively. The use of tacrine is limited as it may cause an increase in the level of serum aminotransferase, which is connected to intense liver harm. On the other hand, donepezil is a more favorable AChE inhibitor since it has some advantages such as non-hepatotoxicity, and the lowest number of side effects when consumed once daily [<xref rid="B15-molecules-23-02033" ref-type="bibr">15</xref>]. Thus, several studies on compounds structurally related to tacrine were performed to discover new BChE inhibitors with reduced side effects [<xref rid="B16-molecules-23-02033" ref-type="bibr">16</xref>,<xref rid="B17-molecules-23-02033" ref-type="bibr">17</xref>,<xref rid="B18-molecules-23-02033" ref-type="bibr">18</xref>,<xref rid="B19-molecules-23-02033" ref-type="bibr">19</xref>,<xref rid="B20-molecules-23-02033" ref-type="bibr">20</xref>,<xref rid="B21-molecules-23-02033" ref-type="bibr">21</xref>,<xref rid="B22-molecules-23-02033" ref-type="bibr">22</xref>,<xref rid="B23-molecules-23-02033" ref-type="bibr">23</xref>]</p><p>It was reported that anticholinesterase agents ought to feature a central ring, a basic region, and a suitable connection between the central ring and basic region, such as O, CH<sub>2</sub>, CONH, and CONH(CH<sub>2</sub>)n, to satisfy the main structural necessity for active and strong enzyme inhibitors [<xref rid="B15-molecules-23-02033" ref-type="bibr">15</xref>]. In addition, the bulky moieties were reported to possess good anti-BChE activity, which may be related to the ability of BChE to ideally bind with bigger substituents, as its structure is composed of a more open core [<xref rid="B24-molecules-23-02033" ref-type="bibr">24</xref>]. Furthermore, there are no reported data on 9-aminoacridine and its acetylated analogs as anticholinesterase inhibitors until this study. Based on this empirical knowledge, we aimed to improve BChE inhibitory activity via the design of new compounds bearing the following structural properties: 9-aminoacridine as the central ring, heterocyclic rings such as piperazine, piperidine, or morpholine as the basic region, and finally, a (thiocarbamoylthio)acetamide moiety as the connection between the central ring and the basic region (<xref ref-type="fig" rid="molecules-23-02033-f001">Figure 1</xref>). Thus, the aim was to synthesize new hybrids of 9-aminoacridine and dithiocarbamates analogs as anticholinesterase agents.</p></sec><sec id="sec2-molecules-23-02033"><title>2. Results and Discussion</title><sec id="sec2dot1-molecules-23-02033"><title>2.1. Chemistry</title><p>The newly synthesized derivatives (<bold>4a</bold>&#8211;<bold>4u</bold>) were obtained by taking advantage of the three-step protocol as outlined in <xref ref-type="scheme" rid="molecules-23-02033-sch001">Scheme 1</xref>. The treatment of <italic>N</italic>-(9-acridinyl)-2-chloroacetamide derivatives (<bold>2</bold>) with the appropriate sodium <italic>N</italic>-substituted piperazine/piperidine/morpholine dithiocarbamates (<bold>3</bold>) gave the target compounds with yields of 81.0&#8211;97.0%. The structures of all synthesized compounds were elucidated using infrared (IR), high-resolution mass spectrometry (HRMS), <sup>1</sup>H-NMR, and <sup>13</sup>C-NMR spectroscopic methods. All compounds indicated logical, analytical, and spectroscopic information strongly correlating with their structures.</p></sec><sec id="sec2dot2-molecules-23-02033"><title>2.2. Enzymatic Inhibition</title><p>The results of biological assays were evaluated to understand the inhibitory potency of the newly synthesized compounds (<bold>4a</bold>&#8211;<bold>4u</bold>) against cholinesterase enzymes of different species (AChE from <italic>Electrophorus electricus</italic> and human cells, and BChE from equine and human cells). In order to acquire effective knowledge about structure activity relationship (SAR), compounds <bold>4a</bold>&#8211;<bold>4u</bold> were divided into two classes as derivatives containing piperazine (<bold>4a</bold>&#8211;<bold>4q</bold>) and morpholine or piperidine (<bold>4r</bold>&#8211;<bold>4u</bold>). The assay was performed in two steps. Firstly, compounds <bold>4a</bold>&#8211;<bold>4u</bold> were tested at 10<sup>&#8722;3</sup> and 10<sup>&#8722;4</sup> M concentrations. The second step was performed by using 10<sup>&#8722;5</sup>&#8211;10<sup>&#8722;9</sup> M concentrations of selected compounds that indicated more than 50% inhibitory activity at the initial concentrations. It was clearly observed that similar results were obtained against both species of AChE and BChE. The reason for this similarity was thought to be high degree of homology in the enzymes of the studied species (<xref ref-type="app" rid="app1-molecules-23-02033">Supplementary Materials</xref> and <xref rid="molecules-23-02033-t001" ref-type="table">Table 1</xref>).</p><p>Our in-depth analysis showed that the incorporation of a 9-aminoacridine moiety into the designed compounds contributed weakly to the AChE inhibitory activity; however, it strongly increased the inhibitory activity toward BChE (<xref ref-type="app" rid="app1-molecules-23-02033">Supplementary Materials</xref> and <xref rid="molecules-23-02033-t001" ref-type="table">Table 1</xref>).</p><p>Compounds in the first class (<bold>4a</bold>&#8211;<bold>4q</bold>) offered inhibitory activity with an IC<sub>50</sub> ranging from 0.014 to 2.097 &#181;M against BChE. Compounds <bold>4a</bold>, <bold>4b</bold>, <bold>4e</bold>, <bold>4i</bold>, <bold>4m</bold>, <bold>4n</bold>, and <bold>4o</bold> possessing piperazine with 2-dimethylaminoethyl, 3-dimethylaminopropyl, 2-hydroxyethyl, 4-chlorophenyl, 4-benzhydryl, 4-(trifluoromethyl)benzyl, and 4-methylbenzyl respectively, showed more potent BChE inhibitory activity than other derivatives in the series. Furthermore, the most active compound, <bold>4m</bold> (IC<sub>50</sub>: 0.092 &#181;M), exhibited 15.4-fold better BChE inhibition in comparison with the positive control, donepezil (IC<sub>50</sub>: 1.419 &#181;M). In the second class of compounds, the replacement of piperazine with its bioisosters, namely morpholine (<bold>4r</bold>) and piperidine (<bold>4s</bold>, <bold>4t</bold>, and <bold>4u</bold>), did not significantly enhance the activity against either AChE or BChE.</p><p>In terms of SAR, it can be concluded that the variation of secondary amines such as piperazine, piperidine, and morpholine does not affect the enzyme inhibitory potency of the final compounds. However, the substituents on these cyclic amines are mainly responsible for the biological activity. Although the structures of the compounds show great similarities, the presence of trifluoromethyl in compound <bold>4n</bold> significantly influenced the activity. The better inhibitory profile of <bold>4n</bold> than aminoacridine (<xref rid="molecules-23-02033-t001" ref-type="table">Table 1</xref>) also supports this finding. Thus, it can be suggested that the trifluoromethyl group possesses the ability to form interactions in the enzyme&#8217;s active site.</p><p>It was reported that BChE contains residues which permit bulkier substrates to enter into the active site [<xref rid="B25-molecules-23-02033" ref-type="bibr">25</xref>]. Due to the presence of an acridine ring, the synthesized compounds are big molecules; thus, they may have a higher tendency to inhibit BChE compared to AchE. This situation is also reflected in <xref rid="molecules-23-02033-t001" ref-type="table">Table 1</xref>. At 10<sup>&#8722;4</sup> M concentration, all compounds possessed higher inhibition against BChE<bold>,</bold> indicating that the synthesized compounds had more selectivity toward BChE than AcHE.</p></sec><sec id="sec2dot3-molecules-23-02033"><title>2.3. Kinetics Characterization of BChE Inhibition</title><p>Recognizing the types of enzyme inhibitors is vital; however, much of the drug discovery process focuses instead upon deciding whether one inhibitor is more powerful than another. The two most basic values for evaluating the inhibitor&#8217;s power and characteristics are IC<sub>50</sub> and K<sub>i</sub> [<xref rid="B26-molecules-23-02033" ref-type="bibr">26</xref>].</p><p>To recognize the inhibition type, enzyme kinetics studies were applied using Lineweaver&#8211;Burk plots [<xref rid="B27-molecules-23-02033" ref-type="bibr">27</xref>]. For this purpose, we selected compound <bold>4n</bold>, which showed the best activity against human BChE. There are four different points on the graphs showing the presence (at concentrations of IC<sub>50</sub>/2, IC<sub>50</sub>, and 2 &#215; IC<sub>50</sub>) and absence (control) of <bold>4n</bold>. As seen in <xref ref-type="fig" rid="molecules-23-02033-f002">Figure 2</xref>, every single straight line intersected in the second quadrant of the coordinate axis, which characterizes a typical mixed inhibition. In addition, a graphical examination of the corresponding Lineweaver&#8211;Burk plot shows both increased slopes (decreased V<sub>max</sub>) and intercepts (higher K<sub>m</sub>) at higher inhibitor concentration. This pattern also indicates a mixed-type inhibition.</p><p>The calculation of the inhibition constant (K<sub>i</sub>) is an effective tool for measuring the affinity of an enzyme for its substrate, and it is easily determined using the secondary plots of the Lineweaver&#8211;Burk equation. Hence, a graphical investigation for the lead compound, <bold>4n</bold>, was performed and is presented in <xref ref-type="fig" rid="molecules-23-02033-f003">Figure 3</xref>. It was determined that <bold>4n</bold> has a very close K<sub>i</sub> value (0.017 &#181;M) to that of tacrine [<xref rid="B28-molecules-23-02033" ref-type="bibr">28</xref>], meaning that it is able to firmly bind to the BChE active site.</p><p>When the small molecule binds to the BChE catalytic active site (CAS), the type of inhibition of the enzyme is classified as competitive; by contrast, when the small-molecule interacts with the peripheral anionic site (PAS), the enzymatic inhibition is called non-competitive. Furthermore, once the active molecule acts on both CAS and PAS, the enzymatic inhibition is designated as mixed inhibition [<xref rid="B29-molecules-23-02033" ref-type="bibr">29</xref>]. In this manner, the enzyme kinetics study suggests that compound <bold>4n</bold> interacts with both BChE functional sites, CAS and PAS [<xref rid="B30-molecules-23-02033" ref-type="bibr">30</xref>].</p></sec><sec id="sec2dot4-molecules-23-02033"><title>2.4. Molecular Docking</title><p>So as to explore a possible interacting mode of the lead compound, <bold>4n</bold>, and to evaluate the effects of structural modifications on the BChE enzyme activity, molecular docking was performed and carried out using the X-ray crystal structure of human BChE in complex with tacrine (Protein Data Bank identifier (PDB ID): 4BDS) [<xref rid="B31-molecules-23-02033" ref-type="bibr">31</xref>]. Firstly, tacrine was docked in the enzyme&#8217;s active site to validate the docking procedure. Thus, the &#960;&#8211;&#960; interaction between the aromatic ring of tacrine and the indole of Trp82, and the hydrogen bond between the 9-amino group of tacrine and the carbonyl of His438 were established, as reported in the literature [<xref rid="B31-molecules-23-02033" ref-type="bibr">31</xref>].</p><p>The docking poses of compound <bold>4n</bold>, showing two- and three-dimensional interactions, are presented in <xref ref-type="fig" rid="molecules-23-02033-f004">Figure 4</xref> and <xref ref-type="fig" rid="molecules-23-02033-f005">Figure 5</xref>. According to the poses, there are three main patterns of interaction. The first one is a &#960;&#8211;&#960; interaction between the phenyl moiety and the imidazole of His438 in the catalytic site of the BChE enzyme, almost identical to that of tacrine. The second pattern involves a hydrogen bond between the amide carbonyl and the amino group of Thr120. The last and probably the most important interaction is another hydrogen bond between the three-fluoro methyl substituent of <bold>4n</bold> and the amino group of Gly115. These results demonstrate that <bold>4n</bold> has a significant potency to strongly bind to BChE. In particular, the last interaction clarifies why compound <bold>4n</bold> is more active than other derivatives in the series. Findings of the docking analyses confirmed the data reporting that the bulky moieties have good anti-BChE activity due to their binding ability in the active site of BChE [<xref rid="B24-molecules-23-02033" ref-type="bibr">24</xref>,<xref rid="B25-molecules-23-02033" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot5-molecules-23-02033"><title>2.5. MTT Cell Viability Assay and Selectivity Indexes</title><p>The active compounds (<bold>4a</bold>, <bold>4b</bold>, <bold>4e</bold>, <bold>4i</bold>, <bold>4m</bold>, <bold>4n</bold>, <bold>4o</bold>, and <bold>4t</bold>) were chosen to determine their cytotoxic activity toward a murine fibroblast healthy cell line (NIH3T3). After incubating the cells with active compounds at concentrations of 0.000316 &#181;M to1000 &#181;M for 24 h, the cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay [<xref rid="B15-molecules-23-02033" ref-type="bibr">15</xref>]. The inhibition percentage was calculated for each concentration of the test compounds. The IC<sub>50</sub> values of the compounds were determined using a non-linear regression analysis over the calculated percentage inhibition values, and they are presented in <xref rid="molecules-23-02033-t002" ref-type="table">Table 2</xref>. Accordingly, the cytotoxicity test proposed that the active derivatives were nontoxic against NIH3T3 cells at their active concentrations against BChE.</p></sec><sec id="sec2dot6-molecules-23-02033"><title>2.6. BBB Permeability and Drug-Likeness Score (DLS)</title><p>BBB permeability is exceptionally fundamental for medications that particularly target and focus on the CNS. The failure of medication particles to penetrate the BBB constitutes a major obstacle for CNS drug candidates and ought to be considered in new drug discovery efforts. For this reason, the BBB permeability of the most active derivatives was computed by a CBLigand-BBB forecast server. This predictor uses two different algorithms, AdaBoost and a support vector machine (SVM), combining with four different fingerprints, employed to predict if a compound can pass (+) or cannot pass (&#8722;) the BBB. As presented in <xref rid="molecules-23-02033-t003" ref-type="table">Table 3</xref>, all calculations for the selected compounds resulted in BBB permeability (+), which is necessary for compounds planning to act as ChE inhibitors [<xref rid="B32-molecules-23-02033" ref-type="bibr">32</xref>]. The drug-likeness scores (DLS) were additionally calculated for all active compounds using Molsoft&#8217;s chemical fingerprint mode consisting of 5000 marketed drugs from the World Drug Index (positives) and 10,000 carefully selected non-drug compounds (negatives) [<xref rid="B33-molecules-23-02033" ref-type="bibr">33</xref>] According to this program, the DLS scores were observed between 1.26 and 2.21, which establishes and fortifies their therapeutic significance in future studies.</p></sec></sec><sec id="sec3-molecules-23-02033"><title>3. Materials and Methods</title><sec id="sec3dot1-molecules-23-02033"><title>3.1. Chemistry</title><p>All chemicals were purchased from Sigma-Aldrich Chemicals (Sigma-Aldrich Corp., St. Louis, MO, USA) or Merck Chemicals (Merck KGaA, Darmstadt, Germany). Melting points of the synthesized compounds were assessed with an MP90 digital melting point apparatus (Mettler Toledo, Columbus, OH, USA), and were uncorrected. The <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were recorded on a Bruker Fourier 300 (Bruker Bioscience, Billerica, MA, USA) in DMSO-<italic>d</italic><sub>6.</sub> The IR spectra were obtained on a Shimadzu, IR Affinity 1S (Shimadzu, Kyoto, Japan). The mass spectra of the compounds were taken in negative and positive mode using electron spray ionization (ESI) in LCMS/IT/TOF (Shimadzu, Kyoto, Japan) from the solutions of the samples in methanol. The purities of compounds were checked using thin-layer chromatography (TLC) on silica gel 60 F254 (Merck KGaA, Darmstadt, Germany).</p><sec id="sec3dot1dot1-molecules-23-02033"><title>3.1.1. General Procedure for the Synthesis of <italic>N</italic>-(9-Acridinyl)-2-Chloroacetamide Derivatives (<bold>2</bold>) </title><p>Chloroacetyl chloride (30 mmol, 2.4 mL) in THF (10 mL) was added dropwise while stirring to a mixture of 9-aminoacridine (<bold>1</bold>; 20 mmol, 3.9 g) and triethylamine (40 mmol, 5.6 mL) in THF (50 mL) at 0&#8211;5 &#176;C and stirred for 4 h. The solvent was evaporated under reduced pressure. The residue was washed with water to remove triethylamine hydrochloride, before being dried and crystallized from ethanol [<xref rid="B34-molecules-23-02033" ref-type="bibr">34</xref>].</p></sec><sec id="sec3dot1dot2-molecules-23-02033"><title>3.1.2. General Procedure for the Synthesis of Sodium <italic>N</italic>-Substituted Piperazine/Morpholine/Piperidine Dithiocarbamates (<bold>3a</bold>&#8211;<bold>3u</bold>)</title><p>An ethanolic solution (10 mL) of sodium hydroxide (10 mmol, 0.4 g) was added to an ethanolic solution (10 mL) of the secondary amine (10 mmol). The mixture was cooled in an ice bath; additionally, carbon disulfide (100 mmol, 6.0 mL) was added dropwise with continuous stirring for 1 h at room temperature. The precipitates were filtrated and washed with diethyl ether to obtain a white to pale-yellow-colored product in 70&#8211;90% yield [<xref rid="B14-molecules-23-02033" ref-type="bibr">14</xref>].</p></sec><sec id="sec3dot1dot3-molecules-23-02033"><title>3.1.3. General Procedure for the Synthesis of 2-(9-Acridinylamino)-2-Oxoethyl 4-Piperazinyl/Morpholinyl/Piperidinylcarbodithioate Derivatives (<bold>4a</bold>&#8211;<bold>4u</bold>) </title><p>An equimolar quantity (5 mmol) of appropriate sodium <italic>N</italic>,<italic>N</italic>-disubstituted dithiocarbamate (<bold>3</bold>) and of <italic>N</italic>-(9-acridinyl)-2-chloroacetamide (<bold>2</bold>) in acetone (10 mL) were refluxed for 8 h. The mixture was cooled, and the precipitate was filtrated. The residue was washed with water, before being dried and crystallized from ethanol to obtain the final products [<xref rid="B14-molecules-23-02033" ref-type="bibr">14</xref>].</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(2-(dimethylamino)ethyl)piperazine-1-carbodithioate</italic> (<bold>4a</bold>). Yield: 88.5%; melting poing (m.p.): 200.6 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3269 (amide N&#8211;H), 2769&#8211;2972 (aliphatic C&#8211;H), 1662 (C=O), 1463&#8211;1506 (C=N and C=C), 1232 (C=S), 756 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 2.17&#8211;2.18 (6H, d, <italic>J =</italic> 2.4 Hz, N(<underline>CH<sub>3</sub></underline>)<sub>2</sub>), 2.43&#8211;2.44 (4H, t, <italic>J =</italic> 2.5 Hz, <underline>CH<sub>2</sub></underline>&#8211;<underline>CH<sub>2</sub></underline>), 2.48&#8211;2.55 (4H, m, piperazine C<sub>3</sub><sub>,5</sub>&#8211;H), 3.97 and 4.25 (4H, two bs, piperazine C<sub>2</sub><sub>,6</sub>&#8211;H), 4.62 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.57&#8211;7.62 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.7 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.25&#8211;8.28 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.06 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 45.7 (CH<sub>3</sub>), 50.4 (CH<sub>2</sub>), 51.6 (CH<sub>2</sub>), 52.9 (CH<sub>2</sub>), 55.2 (CH<sub>2</sub>), 56.8 (CH<sub>2</sub>), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 194.9 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>29</sub>N<sub>5</sub>OS<sub>2</sub>: 468.1886, found 468.1874.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(3-(dimethylamino)propyl)piperazine-1-carbodithioate</italic> (<bold>4b</bold>). Yield: 85.7%; m.p.: 153.8 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3340 (amide N&#8211;H), 2777&#8211;2947 (aliphatic C&#8211;H), 1653 (C=O), 1411&#8211;1458 (C=N and C=C), 1209&#8211;1263 (C=S), 758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 1.47&#8211;1.56 (2H, m, CH<sub>2</sub>&#8211;<underline>CH<sub>2</sub></underline>&#8211;CH<sub>2</sub>), 2.08 (6H, s, N<underline>(CH<sub>3</sub></underline>)<sub>2</sub>), 2.15&#8211;2.20 (2H, t, <italic>J =</italic> 7.1 Hz, CH<sub>2</sub>&#8211;CH<sub>2</sub><underline>CH<sub>2</sub></underline>N(CH<sub>3</sub>)<sub>2</sub>), 2.24&#8211;2.29 (2H, d, <italic>J =</italic> 7.4 Hz, <underline>CH<sub>2</sub></underline>CH<sub>2</sub>CH<sub>2</sub>), 2.41&#8211;2.42 (4H, d, <italic>J =</italic> 0.9, piperazine C<sub>3</sub><sub>,</sub><sub>5</sub>&#8211;H), 3.98 and 4.26 (4H, two s, piperazine C<sub>2</sub><sub>,</sub><sub>6</sub>&#8211;H), 4.65 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.57&#8211;7.62 (2H, q, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 7.81&#8211;7.87 (2H, m, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.26&#8211;8.29 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 11.19 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 24.9 (CH<sub>2</sub>), 45.7 (CH<sub>2</sub>), 50.4 (CH<sub>3</sub>), 51.6 (CH<sub>2</sub>), 52.9 (CH<sub>2</sub>), 55.2 (CH<sub>2</sub>), 56.7 (CH<sub>2</sub>), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 194.9 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>31</sub>N<sub>5</sub>OS<sub>2</sub>: 482.2043, found 482.2047.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-ethylpiperazine-1-carbodithioate</italic> (<bold>4c</bold>). Yield: 81.0%; m.p.: 221.7 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3232 (amide N&#8211;H), 2358&#8211;2974 (aliphatic C&#8211;H), 1654 (C=O), 1435&#8211;1508 (C=N and C=C), 1219&#8211;1271 (C=S), 732&#8211;758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 0.98&#8211;1.03 (3H, t, <italic>J =</italic> 7.2 Hz, CH<sub>2</sub><underline>CH<sub>3</sub></underline>), 2.33&#8211;2.40 (2H, q, <italic>J =</italic> 7.2 Hz, <underline>CH<sub>2</sub></underline>CH<sub>3</sub>), 2.47&#8211;2.50 (4H, m, piperazine C<sub>3</sub><sub>,5</sub>&#8211;H), 3.98 and 4.26 (4H, two s, piperazine C<sub>2</sub><sub>,6</sub>&#8211;H), 4.65 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.57&#8211;7.62 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.81&#8211;7.87 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.26&#8211;8.29 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.19 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 12.3 (CH<sub>3</sub>), 50.9 (CH<sub>2</sub>), 51.1 (CH<sub>2</sub>), 51.5 (CH<sub>2</sub>), 52.2 (CH<sub>2</sub>), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (C), 140.7 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.0 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H] <sup>+</sup> calculated for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>OS<sub>2</sub>: 425.1464, found 425.1459.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(4-nitrophenyl)piperazine-1-carbodithioate</italic> (<bold>4d</bold>). Yield: 90.5%; m.p.: 248.2 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3238 (amide N&#8211;H), 2976 (aliphatic C&#8211;H), 1670 (C=O), 1417&#8211;1598 (C=N and C=C), 1213&#8211;1280 (C=S),752 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.74 (4H, s, piperazine C<sub>3</sub><sub>,5</sub>&#8211;H), 4.19 and 4.42 (4H, two bs, piperazine C<sub>2</sub><sub>,6</sub>&#8211;H), 4.68 (2H, s, CO<underline>CH<sub>2</sub></underline>), 6.93&#8211;6.96 (2H, d, <italic>J =</italic> 9.5 Hz, Ar&#8211;H), 7.59&#8211;7.63 (2H, t, <italic>J =</italic> 6.6 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.7 Hz, Ar&#8211;H), 8.07&#8211;8.10 (2H, d, <italic>J =</italic> 9.4 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.27&#8211;8.30 (2H, d, <italic>J =</italic> 8.5 Hz, Ar&#8211;H), 11.10 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 45.2 (CH<sub>2</sub>), 48.9 (CH<sub>2</sub>), 50.6 (CH<sub>2</sub>), 112.3 (C), 123.2 (CH), 125.4 (CH), 126.2 (CH), 126.3 (CH), 129.6 (CH), 130.9 (CH), 137.3 (C), 140.6 (C), 149.4 (C), 154.2 (C-9 in 9-aminoacridine), 167.3 (C=O), 195.4 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S<sub>2</sub>: 518.1315, found 518.1299.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(2-hydroxyethyl)piperazine-1-carbodithioate</italic> (<bold>4e</bold>). Yield: 84.4%; m.p.: 219.2 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3226 (amide N&#8211;H), 2978 (aliphatic C&#8211;H), 1660 (C=O), 1433&#8211;1558 (C=N and C=C), 1228 (C=S), 758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 2.49&#8211;2.50 (2H, t, <italic>J =</italic> 1.7 Hz, OH&#8211;CH<sub>2</sub>&#8211;<underline>CH<sub>2</sub></underline>&#8211;), 2.61 (4H, s, piperazine C<sub>3</sub><sub>,5</sub>&#8211;H), 3.54 (2H, s, OH&#8211;<underline>CH<sub>2</sub></underline>&#8211;CH<sub>2</sub>&#8211;), 4.00 and 4.28 (4H, s, piperazine C<sub>2</sub><sub>,6</sub>&#8211;H), 4.64 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.58&#8211;7.62 (2H, t, <italic>J =</italic> 7.4 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.4 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 8.26&#8211;8.28 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.10 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 50.2 (CH<sub>2</sub>), 51.4 (CH<sub>2</sub>), 52.9 (CH<sub>2</sub>), 58.8 (CH<sub>2</sub>), 59.8 (CH<sub>2</sub>), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.1 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H] <sup>+</sup> calculated for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub>: 441.1413, found 441.1406.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-phenylpiperazine-1-carbodithioate</italic> (<bold>4f</bold>). Yield: 94.5%; m.p.: oil; FTIR (ATR, cm<sup>&#8722;1</sup>): 3352 (amide N&#8211;H), 2881 (aliphatic C&#8211;H), 1660 (C=O), 1417&#8211;1506 (C=N and C=C), 1228 (C=S), 756&#8211;883 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.31&#8211;3.35 (4H, d, <italic>J</italic> =9.4 Hz, piperazine C<sub>3</sub><sub>,5</sub>&#8211;H), 4.15 and 4.42 (4H, two bs, piperazine C<sub>2</sub><sub>,6</sub>&#8211;H), 4.66 (2H, s, CO<underline>CH<sub>2</sub></underline>), 6.78&#8211;6.83 (1H, t, <italic>J =</italic> 7.2 Hz, Ar&#8211;H), 6.94&#8211;6.97 (2H, d, <italic>J =</italic> 8.0 Hz, Ar&#8211;H), 7.21&#8211;7.26 (2H, t, <italic>J =</italic> 7.9 Hz, Ar&#8211;H), 7.58&#8211;7.63 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 7.82&#8211;7.86 (2H, t, <italic>J</italic> = 6.7 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.27&#8211;8.30 (2H, d, <italic>J =</italic> 8.5 Hz, Ar&#8211;H), 11.08 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 48.1 (CH<sub>2</sub>), 50.1 (CH<sub>2</sub>), 51.3 (CH<sub>2</sub>), 115.9 (C), 119.7 (CH), 123.2 (CH), 125.4 (CH), 126.2 (CH), 129.5 (CH), 129.6 (CH), 130.9 (CH), 140.6 (C), 149.4 (C), 150.5 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.3 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H] <sup>+</sup> calculated for C<sub>26</sub>H<sub>24</sub>N<sub>4</sub>OS<sub>2</sub>: 473.1464, found 473.1471.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-methylpiperazine-1-carbodithioate</italic> (<bold>4g</bold>). Yield: 95.3%; m.p.: 243.2 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3226 (amide N&#8211;H), 2783&#8211;2976 (aliphatic C&#8211;H), 1651 (C=O), 1435&#8211;1571(C=N and C=C), 1224&#8211;1288 (C=S), 758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 2.21 (3H, s, CH<sub>3</sub>), 2.42&#8211;2.45 (4H, t, <italic>J =</italic> 4.5 Hz, piperazine C<sub>3</sub><sub>,5</sub>&#8211;H), 3.99 and 4.27 (4H, two s, piperazine C<sub>2</sub><sub>,6</sub>&#8211;H), 4.61 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.58&#8211;7.63 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.3 Hz, Ar&#8211;H), 8.15&#8211;8.18 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.25&#8211;8.28 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 10.94 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 45.6 (CH<sub>2</sub>), 50.3 (CH<sub>3</sub>), 51.6 (CH<sub>2</sub>), 54.5 (CH<sub>2</sub>), 123.2 (CH), 125.3 (CH), 126.3 (CH), 129.3 (CH), 130.9 (CH), 140.5 (CH), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.1 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>OS<sub>2</sub>: 411.1308, found 411.1307.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(4-methoxyphenyl)piperazine-1-carbodithioate</italic> (<bold>4h</bold>). Yield: 89.4%; m.p.: 243.8 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3284 (amide N&#8211;H), 3057&#8211;2945 (aliphatic C&#8211;H), 1664 (C=O), 1431&#8211;1508 (C=N and C=C), 1215 (C=S), 707&#8211;756 (out-of-plane C&#8211;H bending), <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.16&#8211;3.35 (4H, s, piperazine C<sub>3,5</sub>&#8211;H), 3.68 (3H, s, O<underline>CH<sub>3</sub></underline>), 4.14 and 4.42 (4H, two s, piperazine C<sub>2,6</sub>&#8211;H), 4.66 (2H, s, CO<underline>CH<sub>2</sub></underline>), 6.81&#8211;6.84 (2H, d, <italic>J =</italic> 8.5 Hz, Ar&#8211;H), 6.90&#8211;6.93 (2H, d, <italic>J =</italic> 8.4 Hz, Ar&#8211;H), 7.59&#8211;7.64 (2H, t, <italic>J =</italic> 7.3 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.4 Hz, Ar&#8211;H), 8.16&#8211;8.18 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 8.27&#8211;8.30 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 10.97 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 49.8 (CH<sub>2</sub>), 51.4 (CH<sub>2</sub>), 55. 7 (CH<sub>3</sub>), 60.21 (CH<sub>2</sub>), 114.8 (C), 118.7 (CH), 123.2 (CH), 125.3 (CH), 126.3 (CH), 129.6 (CH), 130.9 (CH), 140.5 (C), 144.9 (C), 149.4 (C), 153.9 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.3 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H] <sup>+</sup> calculated for C<sub>27</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>S<sub>2</sub>: 503.1570, found 503.1547.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(4-chlorophenyl)piperazine-1-carbodithioate</italic> (<bold>4i</bold>). Yield: 97.0%; m.p.: 213.6 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3223 (amide N&#8211;H), 2706&#8211;2912 (aliphatic C&#8211;H), 1672 (C=O), 1417&#8211;1573 (C=N and C=C), 1226 (C=S), 815 (para aromatic substitution), 756 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 2.44&#8211;2.50 (4H, q, <italic>J =</italic> 5.8 Hz, piperazine C<sub>3,5</sub>&#8211;H), 4.02 and 4.45 (4H, two bs, piperazine C<sub>2,6</sub>&#8211;H), 4.60 (2H, s, CO<underline>CH<sub>2</sub></underline>), 6.97&#8211;7.00 (2H, d, <italic>J =</italic> 9.1 Hz, Ar&#8211;H), 7.25&#8211;7.28 (2H, d, <italic>J =</italic> 9.0 Hz, Ar&#8211;H), 7.57&#8211;7.62 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.81&#8211;7.85 (2H, t, <italic>J =</italic> 5.9 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.27&#8211;8.30 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.22 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 45.6 (CH<sub>2</sub>), 49.8 (CH<sub>2</sub>), 51.0 (CH<sub>2</sub>), 117.3 (CH), 118.0 (CH), 123.2 (CH), 125.2 (CH), 126.2 (CH), 129.2 (CH), 129.3 (CH), 129.6 (CH), 130.9 (CH), 140.7 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.3 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H] <sup>+</sup> calculated for C<sub>26</sub>H<sub>23</sub>ClN<sub>4</sub>OS<sub>2</sub>: 507.1075, found 507.1069.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(pyrimidin-2-yl)piperazine-1-carbodithioate</italic> (<bold>4j</bold>). Yield: 84.3%; m.p.: 248.4 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3263 (amide N&#8211;H), 2852&#8211;2897 (aliphatic C&#8211;H), 1662 (C=O), 1425&#8211;1583 (C=N and C=C), 1222&#8211;1257 (C=S), 759&#8211;792 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.91 (4H, s, piperazine C<sub>3,5</sub>&#8211;H), 4.13 and 4.38 (4H, two s, piperazine C<sub>2,6</sub>&#8211;H), 4.68 (2H, s, CO<underline>CH<sub>2</sub></underline>), 6.67&#8211;6.70 (1H, t, <italic>J =</italic> 4.7 Hz, Ar&#8211;H), 7.58&#8211;7.63 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.4 Hz, Ar&#8211;H), 8.14&#8211;8.18 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.27&#8211;8.30 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 8.39&#8211;8.41 (2H, d, <italic>J =</italic> 4.7 Hz, Ar&#8211;H), 11.16 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 43.0 (CH<sub>2</sub>), 49.8 (CH<sub>2</sub>), 51.2 (CH<sub>2</sub>), 111.1 (C), 123.2 (CH), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (C), 149.4 (CH), 158.48 (C), 161.3 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.4 (C=S). HRMS (<italic>m</italic>/<italic>z</italic>): [M + H] <sup>+</sup> calculated for C<sub>24</sub>H<sub>22</sub>N<sub>6</sub>OS<sub>2</sub>: 475.1369, found 475.1366.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-benzylpiperazine-1-carbodithioate</italic> (<bold>4k</bold>). Yield: 91.4%; m.p.: 222.3 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3248 (amide N&#8211;H), 2818&#8211;2908 (aliphatic C&#8211;H), 1668 (C=O), 1417&#8211;1510 (C=N and C=C), 1230 (C=S), 731&#8211;756 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.53 and 3.99 (4H, two bs, piperazine C<sub>2</sub>,<sub>6</sub>&#8211;H), 4.28 (2H, s, C<sub>6</sub>H<sub>5</sub>&#8211;<underline>CH<sub>2</sub></underline>&#8211;), 4.62 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.26&#8211;7.32 (5H, m, Ar&#8211;H), 7.57&#8211;7.62 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.25&#8211;8.28 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.05 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 50.4 (CH<sub>2</sub>), 51.7 (CH<sub>2</sub>), 52.4 (CH<sub>2</sub>), 61.8 (CH<sub>2</sub>), 123.2 (C), 125.3 (CH), 126.2 (CH), 127.6 (CH), 128.7 (CH), 129.4 (CH), 129.6 (CH), 130.9 (CH), 138.0 (C), 140.6 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.0 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>27</sub>H<sub>26</sub>N<sub>4</sub>OS<sub>2</sub>: 487.1621, found 487.1622.</p><p><italic>2-(9-Acridin-ylamino)-2-oxoethyl 4-cyclohexylpiperazine-1-carbodithioate</italic> (<bold>4l</bold>). Yield: 88.4%; m.p.: 225.4&#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3309 (amide N&#8211;H), 2357&#8211;2931 (aliphatic C&#8211;H), 1676 (C=O), 1469&#8211;1566 (C=N and C=C), 1230&#8211;1274 (C=S), 754&#8211;866 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 1.03&#8211;1.18 (6H, m, cyclohexyl &#8211;CH<sub>2</sub>&#8211;), 1.54&#8211;1.57 (1H, d, <italic>J =</italic> 11.2 Hz, cyclohexyl &#8211;CH&#8211;), 1.72 (4H, s, cyclohexyl &#8211;CH<sub>2</sub>&#8211;), 2.60 (4H, s, piperazine C<sub>3,5</sub>&#8211;H), 3.94 and 4.24 (4H, two bs, piperazine C<sub>2,6</sub>&#8211;H), 4.62 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.57&#8211;7.62 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.25&#8211;8.28 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.04 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 25.7 (CH<sub>2</sub>), 26.3 (CH<sub>2</sub>), 28.8 (CH<sub>2</sub>), 48.6 (CH<sub>2</sub>), 50.9 (CH<sub>2</sub>), 52.2 (CH<sub>2</sub>), 62.7 (CH), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 194.7 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>30</sub>N<sub>4</sub>OS<sub>2</sub>: 479.1934, found 479.1929.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-benzhydrylpiperazine-1-carbodithioate</italic> (<bold>4m</bold>). Yield: 84.3%; m.p.: 137.0 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3246 (amide N&#8211;H), 2355&#8211;2920 (aliphatic C&#8211;H), 1656 (C=O), 1427&#8211;1571 (C=N and C=C), 1226&#8211;1284 (C=S), 705&#8211;758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 2.44&#8211;2.50 (4H, d, <italic>J =</italic> 5.8 Hz, piperazine C<sub>3,5</sub>&#8211;H), 4.02 and 4.28 (4H, two s, piperazine C<sub>2,6</sub>&#8211;H), 4.40 (1H, s, C<sub>12</sub>H<sub>10</sub>&#8211;<underline>CH</underline>&#8211;), 4.60 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.18&#8211;7.23 (3H, t, <italic>J =</italic> 7.0 Hz, Ar&#8211;H), 7.29&#8211;7.32 (4H, t, <italic>J =</italic> 7.4 Hz, Ar&#8211;H), 7.44 (4H, s, Ar&#8211;H), 7.57&#8211;7.62 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 7.82&#8211;7.88 (2H, m, Ar&#8211;H), 7.15&#8211;7.18 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 7.24&#8211;7.27 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.02 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 51.4 (CH<sub>2</sub>), 60.7 (CH<sub>2</sub>), 72.7 (CH<sub>2</sub>), 74.6 (CH), 117.9 (C), 123.1 (CH), 125.4 (CH), 126.3 (CH), 127.6 (CH), 128.1 (CH), 129.1 (CH), 131.2 (CH), 140.9 (C), 142.6 (C), 149.1 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.1 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>33</sub>H<sub>30</sub>N<sub>4</sub>OS<sub>2</sub>: 563.1934, found 563.1924.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(4-(trifluoromethyl)benzyl)piperazine-1-carbodithioate</italic> (<bold>4n</bold>). Yield: 87.7%; m.p.: 161.5 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3232 (amide N&#8211;H), 2814&#8211;2920 (aliphatic C&#8211;H), 1653 (C=O), 1415&#8211;1510 (C=N and C=C), 1219 (C=S), 756 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 2.48&#8211;2.52 (4H, t, <italic>J =</italic> 5.10 Hz, piperazine C<sub>3,5</sub>&#8211;H), 3.62 and 4.00 (4H, two s, piperazine C<sub>2,6</sub>&#8211;H), 4.29 (2H, s, C<sub>6</sub>H<sub>5</sub>&#8211;<underline>CH<sub>2</sub></underline>&#8211;), 4.62 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.55&#8211;7.57 (2H, d, <italic>J =</italic> 7.9 Hz, Ar&#8211;H), 7.60&#8211;7.62 (2H, d, <italic>J</italic> = 7.7 Hz, Ar&#8211;H), 7.68&#8211;7.71 (2H, d, <italic>J =</italic> 8.2 Hz Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.8 Hz, Ar&#8211;H), 7.14&#8211;7.17 (2H, d, <italic>J =</italic> 8.8 Hz, Ar&#8211;H), 7.25&#8211;7.27 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.01 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 52.4 (CH<sub>2</sub>), 60.8 (CH<sub>2</sub>), 72.7 (CH<sub>2</sub>), 125.0 (q, <italic>J =</italic> 214.9 Hz, CF<sub>3</sub>), 123.2 (CH), 125.3 (CH), 125.6 (q, <italic>J</italic> =3.6 Hz, trifluoromethylphenyl C<sub>3,3&#8242;</sub>), 126.2 (CH), 129.6 (CH), 129.9 (q, <italic>J</italic> = 39.8 Hz, trifluoromethylphenyl C<sub>4</sub>), 130.0 (CH), 130.1 (C), 140.6 (C), 143.2 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.1 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>25</sub>F<sub>3</sub> N<sub>4</sub>OS<sub>2</sub>: 555.1495, found 555.1493.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(4-methylbenzyl)piperazine-1-carbodithioate</italic> (<bold>4o</bold>). Yield: 91.0%; m.p.: 205.8 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3255 (amide N&#8211;H), 2792&#8211;2902 (aliphatic C&#8211;H), 1654 (C=O), 1435&#8211;1508 (C=N and C=C), 1220 (C=S), 759 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 2.27 (3H, s, &#8211;CH<sub>3</sub>), 2.47&#8211;2.50 (4H, m, piperazine C<sub>3,5</sub>&#8211;H), 3.47 (2H, s,C<sub>6</sub>H<sub>5</sub>&#8211;<underline>CH<sub>2</sub></underline>), 3.98 and 4.26 (4H, two s, piperazine C<sub>2,6</sub>&#8211;H), 4.63 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.11&#8211;7.14 (2H, d, <italic>J =</italic> 7.9 Hz, Ar&#8211;H), 7.18&#8211;7.20 (2H, d, <italic>J</italic> =7.9 Hz, Ar&#8211;H), 7.56&#8211;7.61 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.86&#8211;7.81 (2H, t, <italic>J =</italic> 7.4 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.25&#8211;8.28 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.15 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 21.2 (CH<sub>3</sub>), 50.4 (CH<sub>2</sub>), 51.6 (CH<sub>2</sub>), 52.4 (CH<sub>2</sub>), 61.5 (CH<sub>2</sub>), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.3 (CH), 129.4 (CH), 129.6 (CH), 130.9 (CH), 134.8 (C), 36.7 (C), 140.6 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.0 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>28</sub>N<sub>4</sub>OS<sub>2</sub>: 501.1777, found 501.1774.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(4-fluorophenyl)piperazine-1-carbodithioate</italic> (<bold>4p</bold>). Yield: 96.4%; m.p.: 227.7 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3257 (amide N&#8211;H), 2800&#8211;2906 (aliphatic C&#8211;H), 1653 (C=O), 1433 (C=N and C=C), 1213 (C=S), 1029 (C&#8211;F), 825 (1,4-disubstituted benzene), 756 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.24&#8211;3.27 (4H, t, <italic>J =</italic> 4.8 Hz, piperazine C<sub>3</sub><sub>,5</sub>&#8211;H), 4.16 and 4.39 (4H, two s, piperazine C<sub>2</sub><sub>,6</sub>&#8211;H), 4.67 (2H, s,CO<underline>CH<sub>2</sub></underline>), 6.94&#8211;6.99 (2H, m, Ar&#8211;H), 7.04&#8211;7.10 (2H, t, <italic>J =</italic> 8.9 Hz, Ar&#8211;H), 7.58&#8211;7.63 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.7 Hz, Ar&#8211;H), 8.15&#8211;8.18 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.27&#8211;8.30 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.07 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 49.0 (CH<sub>2</sub>), 50.1 (CH<sub>2</sub>), 51.36 (CH<sub>2</sub>), 115.9 (d, <italic>J</italic> =21.8 Hz, fluorophenyl C<sub>3,3&#8242;</sub>), 117.9 (d, <italic>J</italic> = 7.5 Hz, fluorophenyl C<sub>2,2&#8242;</sub>), 123.2 (CH), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (CH), 147.4 (d, <italic>J</italic> = 2.3 Hz, fluorophenyl C<sub>1</sub>), 149.4 (C-9 in 9-aminoacridine), 156.8 (d, <italic>J</italic> = 234.8 Hz, fluorophenyl C<sub>4</sub>), 167.4 (C=O), 195.3 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>23</sub>FN<sub>4</sub>OS<sub>2</sub>: 490.62, found 491.13; HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>23</sub>FN<sub>4</sub>OS<sub>2</sub>: 491.1370, found 491.1354.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 4-(furan-2-carbonyl)piperazine-1-carbodithioate</italic> (<bold>4q</bold>). Yield: 95.5%; m.p.: 218.9 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3255 (amide N&#8211;H), 2895&#8211;2995 (aliphatic C&#8211;H), 1653 (furan-2-carbonyl), 1616 (amide C=O), 1423 (C=N and C=C), 1215 (C=S), 758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.88 (4H, s, piperazine C<sub>3,5</sub>&#8211;H), 4.12 and 4.36 (4H, two s, piperazine &#8211;CH<sub>2</sub>), 4.68 (2H, s, CO<underline>CH<sub>2</sub></underline>), 6.64&#8211;6.65 (1H, m, Ar&#8211;H), 7.07&#8211;7.08 (2H, d, <italic>J</italic> = 3.4 Hz, Ar&#8211;H), 7.57&#8211;7.63 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 7.81&#8211;7.87 (3H, t, <italic>J =</italic> 8.1 Hz, Ar&#8211;H), 8.14&#8211;8.17 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.27&#8211;8.30 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.21 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 49.6 (CH<sub>2</sub>), 51.1 (CH<sub>2</sub>), 111.9 (C), 116.6 (CH), 123.2 (CH), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (CH), 145.6 (C), 147.1 (C), 149.4 (C), 159.0 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.7 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S<sub>2</sub>: 491.1206, found 491.1186.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl morpholine-4-carbodithioate</italic> (<bold>4r</bold>). Yield: 89.2%; m.p.: 237.8 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3232 (amide N&#8211;H), 2864&#8211;2949 (aliphatic C&#8211;H), 1653 (amide C=O), 1417&#8211;1423 (C=N and C=C), 1273 (C=S), 1001 (C&#8211;O&#8211;C of morpholine), 864&#8211;758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 3.71&#8211;3.72 (4H, d, <italic>J</italic> = 4.3 Hz, morpholine C<sub>3.5</sub>&#8211;H), 4.01 and 4.25 (4H, two bs, morpholine C<sub>2,6</sub>&#8211;H), 4.65 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.58&#8211;7.63 (2H, t, <italic>J</italic> = 7.5 Hz, Ar&#8211;H), 7.82&#8211;7.87 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 8.15&#8211;8.18 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.26&#8211;8.29 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 11.06 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 50.9 (CH<sub>2</sub>), 51.8 (CH<sub>2</sub>), 66.1 (CH<sub>2</sub>), 123.2 (C), 125.3 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.6 (C), 149.4 (C-9 in 9-aminoacridine), 167.4 (C=O), 195.7 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>20</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S<sub>2</sub>: 398.0991, found 398.0977.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl piperidine-1-carbodithioate</italic> (<bold>4s</bold>). Yield: 84.4%; m.p.: 265.4 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3255 (amide N&#8211;H), 2904&#8211;2983 (aliphatic C&#8211;H), 1653 (amide C=O), 1417 (C=N and C=C), 1217 (C=S), 1001 (C&#8211;N of piperidine), 758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 1.64 (6H, s, piperidine &#8211;CH<sub>2</sub>), 3.96 and 4.25 (4H, two s, piperidine <underline>CH<sub>2</sub></underline>&#8211;N&#8211;<underline>CH<sub>2</sub></underline>), 4.62 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.57&#8211;7.61 (2H, t, <italic>J =</italic> 6.6 Hz, Ar&#8211;H), 7.82&#8211;7.86 (2H, t, <italic>J =</italic> 6.9 Hz, Ar&#8211;H), 8.14&#8211;8.16 (2H, d, <italic>J =</italic> 8.3 Hz, Ar&#8211;H), 8.26&#8211;8.29 (2H, d, <italic>J =</italic> 8.5 Hz, Ar&#8211;H), 11.14 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 23.9 (CH<sub>2</sub>), 26.0 (CH<sub>2</sub>), 51.7 (CH<sub>2</sub>), 53.1 (CH<sub>2</sub>), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9(CH), 140.7 (C), 149.4 (C-9 in 9-aminoacridine), 167.5 (C=O), 193.7 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>21</sub>H<sub>21</sub>N<sub>3</sub>OS<sub>2</sub>: 396.1199, found 396.1184.</p><p><italic>2-(9-Acridinylamino)-2-oxoethyl 2-methylpiperidine-1-carbodithioate</italic> (<bold>4t</bold>). Yield: 93.3%; m.p.: 265.4 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3255 (amide N&#8211;H), 2924 (aliphatic C&#8211;H), 1653 (amide C=O), 1417&#8211;1463 (C=N and C=C), 1215&#8211;1263 (C=S), 1001 (C&#8211;N of piperidine), 758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 1.19&#8211;1.25 (9H, m, piperidine &#8211;CH<sub>2</sub>, &#8211;CH<sub>3</sub>), 4.26&#8211;4.30 (3H, m, piperidine &#8211;CH<sub>2</sub>, &#8211;CH&#8211;), 4.61 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.60 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.85 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 8.16 (2H, d, <italic>J =</italic> 8.6 Hz, Ar&#8211;H), 8.28 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 10.94 (1H, s, &#8211;NH&#8211;); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 18.5 (CH<sub>3</sub>), 18.7 (CH<sub>2</sub>), 25.7 (CH<sub>2</sub>), 26.2 (CH<sub>2</sub>), 52.2 (CH<sub>2</sub>), 54.6 (CH), 123.2 (C), 125.4 (CH), 126.2 (CH), 129.6 (CH), 130.9 (CH), 140.3 (C), 149.4 (C-9 in 9-aminoacridine), 167.6 (C=O), 194.3 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>OS<sub>2</sub>: 410.1355, found 410.1338.</p><p><italic>2-(9-Acridinylamino)-2-Oxoethyl 4-Benzylpiperidine-1-Carbodithioate</italic> (<bold>4u</bold>). Yield: 90.7%; m.p.: 265.4 &#176;C; FTIR (ATR, cm<sup>&#8722;1</sup>): 3261 (amide N&#8211;H), 2852&#8211;2922 (aliphatic C&#8211;H), 1653 (amide C=O), 1452&#8211;1570 (C=N and C=C), 1261 (C=S), 1016 (C&#8211;N of piperidine), 758 (out-of-plane C&#8211;H bending); <sup>1</sup>H-NMR (300 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 1.22&#8211;1.26 (5H, m, piperidine &#8211;CH<sub>2</sub>, &#8211;CH), 3.04&#8211;3.08 (2H, m, piperidine &#8211;CH<sub>2</sub>&#8211;), 3.20&#8211;3.25 (2H, m, piperidine &#8211;CH<sub>2</sub>&#8211;), 3.97 (2H, s, C<sub>6</sub>H<sub>5</sub>&#8211;<underline>CH<sub>2</sub></underline>&#8211;), 4.61 (2H, s, CO<underline>CH<sub>2</sub></underline>), 7.58 (2H, t, <italic>J =</italic> 7.6 Hz, Ar&#8211;H), 7.67 (2H, t, <italic>J =</italic> 7.5 Hz, Ar&#8211;H), 7.77&#8211;7.86 (5H, m, benzyl &#8211;CH), 8.15 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H), 8.28 (2H, d, <italic>J =</italic> 8.7 Hz, Ar&#8211;H); <sup>13</sup>C-NMR (75 MHz, DMSO-<italic>d</italic><sub>6</sub>; &#948;, ppm): 37.1 (CH), 42.0 (CH<sub>2</sub>), 48.7 (CH<sub>2</sub>), 50.6 (CH<sub>2</sub>), 54.6 (CH<sub>2</sub>), 122.4 (C), 125.5 (CH), 126.0 (CH), 126.3 (CH), 128.7 (CH), 129.5 (CH), 130.3 (CH), 130.9 (CH), 132.2 (CH), 140.3 (C), 149.2 (C-9 in 9-aminoacridine), 167.6 (C=O), 193.9 (C=S); HRMS (<italic>m</italic>/<italic>z</italic>): [M + H]<sup>+</sup> calculated for C<sub>28</sub>H<sub>27</sub>N<sub>3</sub>OS<sub>2</sub>: 486.1668, found 486.1654.</p></sec></sec><sec id="sec3dot2-molecules-23-02033"><title>3.2. AChE/BChE Activity Assay</title><p>All enzymes were obtained from Sigma-Aldrich (Steinheim, Germany). Ellman&#8217;s reagent and the substrates were obtained from Fluka (Buchs, Switzerland). The chemicals used to prepare the buffer solution were purchased from Merck (Darmstadt, Germany).</p><p>The enzyme inhibitory activities of the synthesized compounds were investigated by applying Ellman&#8217;s method [<xref rid="B35-molecules-23-02033" ref-type="bibr">35</xref>]. Enzyme solutions were dissolved in gelatin solution (1%; 2.5 units/mL). Compounds <bold>4a</bold>&#8211;<bold>4u</bold> and reference agents were prepared in 2% DMSO at concentrations of 10<sup>&#8722;3</sup> M and 10<sup>&#8722;4</sup> M. The enzyme solution (20 &#181;L/well) and inhibitor solution (20 &#181;L/well) were mixed with buffer (140 &#181;L/well, pH 8 &#177; 0.1) and incubated at 25 &#176;C for 5 min. Then, the reaction was initiated by the addition of Ellman&#8217;s reagent 5,5&#8242;-Dithiobis(2-nitrobenzoic acid) (DTNB; 20 &#181;L/well, 10 mM) and the substrate (10 &#181;L/well, 75 mM). The absorbance was measured for 10 min at 412 nm. The enzyme solution was processed as a control. All readings were adjusted with blank-reading. All assays were performed in four independent wells. The same procedure was applied for further concentrations (10<sup>&#8722;5</sup>&#8211;10<sup>&#8722;9</sup> M) of reference agents and synthesized compounds displaying &#8805;50% inhibition at initial concentrations (10<sup>&#8722;3</sup> and 10<sup>&#8722;4</sup> M). The IC<sub>50</sub> values were calculated by applying regression analyses using Microsoft Excel 2013 [<xref rid="B36-molecules-23-02033" ref-type="bibr">36</xref>]. Absorbance differences between the two readings were taken, and percentage inhibition rates were calculated according to the following formula:<disp-formula id="FD1-molecules-23-02033"><mml:math id="mm1"><mml:mrow><mml:mrow><mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mo>%</mml:mo><mml:mo>&#160;</mml:mo><mml:mi>I</mml:mi><mml:mi>n</mml:mi><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>C</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>A</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>B</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>I</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>A</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>B</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>A</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>C</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>A</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>B</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo></mml:mrow><mml:mtext>&#160;</mml:mtext></mml:mrow></mml:mrow></mml:math></disp-formula></p><list list-type="simple"><list-item><p><bold>Blank (<italic>B</italic>)</bold>: the well in which the inhibitor compound and substrate were not added;</p></list-item><list-item><p><bold>Control (<italic>C</italic>)</bold>: the well where the inhibitor compound was not added;</p></list-item><list-item><p><bold><italic>A</italic>(<italic>B</italic>)</bold>: the difference in absorbance reading for the blank;</p></list-item><list-item><p><bold><italic>A</italic>(<italic>C</italic>)</bold>: the difference in absorbance reading for the control;</p></list-item><list-item><p><bold><italic>A</italic>(<italic>I</italic>)</bold>: the difference in absorbance reading for the inhibitor compounds.</p></list-item></list></sec><sec id="sec3dot3-molecules-23-02033"><title>3.3. Enzyme Kinetics</title><p>In the kinetics studies, the assay protocol specified for the inhibition assay was identical. However, unlike the inhibition method, the concentrations of the most active inhibitor compound, <bold>4n</bold>, were used at the calculated IC<sub>50</sub>/2, IC<sub>50</sub>, and 2 &#215; IC<sub>50</sub> values. The substrate BTCI solution with 10 serial dilutions at different concentrations in the range of 150&#8211;0.2929 mM were prepared and used. Measurements were performed one of two ways, in the presence and in the absence of the inhibitor. Firstly, the solutions of compound <bold>4n</bold> at three different concentrations were added to the wells (20 &#956;L/well). After addition of BChE (20 &#956;L/well), the mixture was incubated under the same conditions as the activity assay. Then, the reaction was initiated by the addition of Ellman&#8217;s reagent (DTNB; 20 &#181;L/well, 10 mM) and the substrate (10 &#181;L/well, 75 mM). The absorbance was measured for 10 min at 412 nm. The enzyme solution was processed as a control. All readings were adjusted with blank-reading. The results were analyzed as Lineweaver&#8211;Burk plots using Microsoft Office Excel 2013 [<xref rid="B15-molecules-23-02033" ref-type="bibr">15</xref>].</p></sec><sec id="sec3dot4-molecules-23-02033"><title>3.4. Molecular Docking</title><p>The docking study was used to discover the binding modes of the most active compound, <bold>4n</bold>, to the BChE active site. The structure of <italic>Homo sapiens</italic> BChE (PDB ID: 4BDS) [<xref rid="B32-molecules-23-02033" ref-type="bibr">32</xref>], including tacrine in the active site, was retrieved from the Protein Data Bank server (<uri xlink:href="www.pdb.org">www.pdb.org</uri>). The structure of <bold>4n</bold> was assembled with the Schr&#246;dinger Maestro (Schr&#246;dinger, 2016) interface [<xref rid="B37-molecules-23-02033" ref-type="bibr">37</xref>], and was then directed to the Protein Preparation Wizard protocol of the Schr&#246;dinger Suite 2016 Update 2 [<xref rid="B38-molecules-23-02033" ref-type="bibr">38</xref>]. The LigPrep 3.8 [<xref rid="B39-molecules-23-02033" ref-type="bibr">39</xref>] software was used to accurately prepare compound <bold>4n</bold> for the assignment of protonation regions at pH 8.0 &#177; 1.0 and the atom types. Bond orders and hydrogen atoms in the structure were fixed as required. The Glide 7.1 program [<xref rid="B40-molecules-23-02033" ref-type="bibr">40</xref>] was used to generate the grid, and docking analyses were carried out using the single-precision docking mode (SP).</p></sec><sec id="sec3dot5-molecules-23-02033"><title>3.5. Cell Viability Assay and Selectivity Indexes</title><p>Healthy murine embryonic fibroblast cells (NIH3T3 cell line) were used for the cytotoxicity tests. The cell line and selected compounds were prepared for an MTT assay as reported previously [<xref rid="B41-molecules-23-02033" ref-type="bibr">41</xref>]. The optical densities (OD) of 96 well plates were recorded at 540 nm. The percentage inhibition was determined for each concentration according to the formula below, and the IC<sub>50</sub> values were calculated by applying regression analyses using Microsoft Excel 2013 [<xref rid="B15-molecules-23-02033" ref-type="bibr">15</xref>].
<disp-formula id="FD2-molecules-23-02033"><mml:math id="mm2"><mml:mrow><mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mo>%</mml:mo><mml:mo>&#160;</mml:mo><mml:mi>I</mml:mi><mml:mi>n</mml:mi><mml:mi>h</mml:mi><mml:mi>i</mml:mi><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>100</mml:mn><mml:mo>&#8722;</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mo>&#160;</mml:mo><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>.</mml:mo></mml:mrow><mml:mtext>&#160;</mml:mtext></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec3dot6-molecules-23-02033"><title>3.6. BBB Permeability and Drug-Likeness Score (DLS)</title><p>With a specific end goal of assessing some important biological parameters for the active compounds (<bold>4a</bold>, <bold>4b</bold>, <bold>4e</bold>, <bold>4i</bold>, <bold>4m</bold>, <bold>4n</bold>, <bold>4o</bold>, and <bold>4t</bold>), BBB permeability and DLS were predicted using an online BBB Predictor and Molsoft&#8217;s chemical fingerprints mode, respectively [<xref rid="B42-molecules-23-02033" ref-type="bibr">42</xref>,<xref rid="B43-molecules-23-02033" ref-type="bibr">43</xref>].</p></sec></sec><sec id="sec4-molecules-23-02033"><title>4. Conclusions</title><p>Due to the complicated nature of AD, scientists are still trying to discover a medication to cure this disease. One possible way of overcoming this disease is through the discovery of new compounds that may be useful in its treatment. Hence, 21 new derivatives of 2-(9-acridinylamino)-2-oxoethyl-piperazinyl/piperidinyl/morpholinylcarbodithioate (<bold>4a</bold>&#8211;<bold>4u</bold>) were designed, synthesized, and screened for their inhibition potential toward ChEs. Eight derivatives (<bold>4a</bold>, <bold>4b</bold>, <bold>4e</bold>, <bold>4i</bold>, <bold>4m</bold>, <bold>4n</bold>, <bold>4o</bold>, and <bold>4t</bold>) demonstrated a specific and promising action against BChE, from which only one compound (<bold>4n</bold>) was able to inhibit both enzymes. BChE kinetics and molecular modeling studies were applied to investigate the binding mode of the lead compound, <bold>4n</bold>, to the enzyme&#8217;s active site. Moreover, the result of cytotoxic activity against NIH3T3 cells indicated that the active derivatives showed no cytotoxicity, suggesting a safety profile of these compounds. Similarly, the BBB permeability and DLS studies indicated the relative success of the most active derivatives. </p></sec></body><back><fn-group><fn><p><bold>Sample Availability:</bold> Samples of the compounds <bold>4a</bold>&#8211;<bold>4u</bold> are available from the authors.</p></fn></fn-group><app-group><app id="app1-molecules-23-02033"><title>Supplementary Materials</title><p>The following are available online, Table S1: Inhibitory Activity (%) of the compounds <bold>4a</bold>&#8211;<bold>4u</bold> against AChE and BChE., Table S2: Inhibitory activity (%) and IC<sub>50</sub> values of the selected compounds against AChE and BChE.</p><supplementary-material content-type="local-data" id="molecules-23-02033-s001"><media xlink:href="molecules-23-02033-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Y.&#214;. and Z.A.K. conceived and designed the experiments; W.H. performed the synthesis; S.L. performed the analysis; B.N.S. performed the activity tests; B.N.S. performed the docking studies; B.K. and S.I. performed the toxicity tests; W.H., B.N.S., S.L., B.K., S.I., Y.&#214;., and Z.A.K. wrote the paper.</p></notes><notes><title>Funding</title><p>This study was financially supported by the Anadolu University Scientific Projects Fund, Project No: 1805S191.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-23-02033"><label>1.</label><element-citation publication-type="web"><article-title>World Alzheimer Report 2015</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.alz.co.uk/research/worldalzheimerreport2015summary.pdf">https://www.alz.co.uk/research/worldalzheimerreport2015summary.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-01-26">(accessed on 26 January 2017)</date-in-citation></element-citation></ref><ref id="B2-molecules-23-02033"><label>2.</label><element-citation publication-type="web"><article-title>Dementia: A Public Health Priority</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/mental_health/publications/dementia_report_2012/en/">http://www.who.int/mental_health/publications/dementia_report_2012/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-01-26">(accessed on 26 January 2017)</date-in-citation></element-citation></ref><ref id="B3-molecules-23-02033"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnikova</surname><given-names>I.</given-names></name></person-group><article-title>Therapies for Alzheimer's disease</article-title><source>Nat. Rev. Drug Discov.</source><year>2007</year><volume>6</volume><fpage>341</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1038/nrd2314</pub-id><?supplied-pmid 17539055?><pub-id pub-id-type="pmid">17539055</pub-id></element-citation></ref><ref id="B4-molecules-23-02033"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname><given-names>S.</given-names></name></person-group><article-title>Advances in the pharmacotherapy of Alzheimer&#8217;s disease</article-title><source>Can. Med. Assoc. J.</source><year>2002</year><volume>166</volume><fpage>616</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">11898943</pub-id></element-citation></ref><ref id="B5-molecules-23-02033"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darvesh</surname><given-names>S.</given-names></name><name><surname>Grantham</surname><given-names>D.L.</given-names></name><name><surname>Hopkins</surname><given-names>D.A.</given-names></name></person-group><article-title>Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation</article-title><source>J. Comp. Neurol.</source><year>1998</year><volume>393</volume><fpage>374</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19980413)393:3&lt;374::AID-CNE8&gt;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">9548556</pub-id></element-citation></ref><ref id="B6-molecules-23-02033"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>M.</given-names></name><name><surname>Kraus</surname><given-names>B.</given-names></name><name><surname>Heilmann</surname><given-names>J.</given-names></name></person-group><article-title>Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties</article-title><source>Bioorg. Med. Chem.</source><year>2008</year><volume>16</volume><fpage>4252</fpage><lpage>4261</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2008.02.083</pub-id><?supplied-pmid 18343673?><pub-id pub-id-type="pmid">18343673</pub-id></element-citation></ref><ref id="B7-molecules-23-02033"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carolan</surname><given-names>C.G.</given-names></name><name><surname>Dillon</surname><given-names>G.P.</given-names></name><name><surname>Khan</surname><given-names>D.</given-names></name><name><surname>Ryder</surname><given-names>S.A.</given-names></name><name><surname>Gaynor</surname><given-names>J.M.</given-names></name><name><surname>Reidy</surname><given-names>S.</given-names></name><name><surname>Marquez</surname><given-names>J.F.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Holland</surname><given-names>V.</given-names></name><name><surname>Gilmer</surname><given-names>J.F.</given-names></name></person-group><article-title>Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor</article-title><source>J. Med. Chem.</source><year>2010</year><volume>53</volume><fpage>1190</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1021/jm9014845</pub-id><?supplied-pmid 20067290?><pub-id pub-id-type="pmid">20067290</pub-id></element-citation></ref><ref id="B8-molecules-23-02033"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawaz</surname><given-names>S.A.</given-names></name><name><surname>Ayaz</surname><given-names>M.</given-names></name><name><surname>Brandt</surname><given-names>W.</given-names></name><name><surname>Wessjohann</surname><given-names>L.A.</given-names></name><name><surname>Westermann</surname><given-names>B.</given-names></name></person-group><article-title>Cation-&#960; and &#960;-&#960; stacking interactions allow selective inhibition of butyrylcholinesterase by modified quinine and cinchonidine alkaloids</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2011</year><volume>404</volume><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.12.084</pub-id><?supplied-pmid 21185266?><pub-id pub-id-type="pmid">21185266</pub-id></element-citation></ref><ref id="B9-molecules-23-02033"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillozet</surname><given-names>A.L.</given-names></name><name><surname>Smiley</surname><given-names>J.F.</given-names></name><name><surname>Mash</surname><given-names>D.C.</given-names></name><name><surname>Mesulam</surname><given-names>M.M.</given-names></name></person-group><article-title>Butyrylcholinesterase in the life cycle of amyloid plaques</article-title><source>Ann. Neurol.</source><year>1997</year><volume>42</volume><fpage>909</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1002/ana.410420613</pub-id><?supplied-pmid 9403484?><pub-id pub-id-type="pmid">9403484</pub-id></element-citation></ref><ref id="B10-molecules-23-02033"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podoly</surname><given-names>E.</given-names></name><name><surname>Shalev</surname><given-names>D.E.</given-names></name><name><surname>Shenhar-Tsarfaty</surname><given-names>S.</given-names></name><name><surname>Bennett</surname><given-names>E.R.</given-names></name><name><surname>Ben Assayag</surname><given-names>E.</given-names></name><name><surname>Wilgus</surname><given-names>H.</given-names></name><name><surname>Livnah</surname><given-names>O.</given-names></name><name><surname>Soreq</surname><given-names>H.</given-names></name></person-group><article-title>The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>17170</fpage><lpage>17179</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.004952</pub-id><?supplied-pmid 19383604?><pub-id pub-id-type="pmid">19383604</pub-id></element-citation></ref><ref id="B11-molecules-23-02033"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z.X.</given-names></name></person-group><article-title>Future perspectives of AD research and clinical practice</article-title><source>Med. Hypotheses</source><year>2004</year><volume>63</volume><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2004.03.001</pub-id><?supplied-pmid 15236794?><pub-id pub-id-type="pmid">15236794</pub-id></element-citation></ref><ref id="B12-molecules-23-02033"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lemke</surname><given-names>T.L.</given-names></name><name><surname>Williams</surname><given-names>D.A.</given-names></name><name><surname>Roche</surname><given-names>V.F.</given-names></name><name><surname>Zito</surname><given-names>S.W.</given-names></name></person-group><source>Foye&#8217;s Principles of Medicinal Chemistry</source><edition>6th ed.</edition><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2008</year></element-citation></ref><ref id="B13-molecules-23-02033"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madalageri</surname><given-names>P.M.</given-names></name><name><surname>Kotresh</surname><given-names>O.</given-names></name></person-group><article-title>Synthesis, DNA protection and antimicrobial activity of some novel chloromethyl benzimidazole derivatives bearing dithiocarbamates</article-title><source>J. Chem. Pharm. Res.</source><year>2012</year><volume>4</volume><fpage>2697</fpage><lpage>2703</lpage></element-citation></ref><ref id="B14-molecules-23-02033"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levent</surname><given-names>S.</given-names></name><name><surname>Acar-&#199;evik</surname><given-names>U.A.</given-names></name><name><surname>Sa&#287;l&#305;k</surname><given-names>B.N.</given-names></name><name><surname>&#214;zkay</surname><given-names>Y.</given-names></name><name><surname>Can</surname><given-names>O.D.</given-names></name><name><surname>&#214;zkay</surname><given-names>U.D.</given-names></name><name><surname>U&#231;ucu</surname><given-names>&#220;.</given-names></name></person-group><article-title>Anticholinesterase activity screening of some novel dithiocarbamate derivatives including piperidine and piperazine moieties</article-title><source>Phosphorus Sulfur Silicon Relat. Elem.</source><year>2017</year><volume>192</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1080/10426507.2016.1259228</pub-id></element-citation></ref><ref id="B15-molecules-23-02033"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demir &#214;zkay</surname><given-names>&#220;.</given-names></name><name><surname>Can</surname><given-names>&#214;.D.</given-names></name><name><surname>Sa&#287;l&#305;k</surname><given-names>B.N.</given-names></name><name><surname>Acar &#199;evik</surname><given-names>U.</given-names></name><name><surname>Levent</surname><given-names>S.</given-names></name><name><surname>&#214;zkay</surname><given-names>Y.</given-names></name><name><surname>Ilg&#305;n</surname><given-names>S.</given-names></name><name><surname>Atl&#305;</surname><given-names>&#214;.</given-names></name></person-group><article-title>Design, synthesis, and AChE inhibitory activity of new benzothiazole&#8211;piperazines</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2016</year><volume>26</volume><fpage>5387</fpage><lpage>5394</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2016.10.041</pub-id><?supplied-pmid 27789142?><pub-id pub-id-type="pmid">27789142</pub-id></element-citation></ref><ref id="B16-molecules-23-02033"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korabecny</surname><given-names>J.</given-names></name><name><surname>Andrs</surname><given-names>M.</given-names></name><name><surname>Nepovimova</surname><given-names>E.</given-names></name><name><surname>Dolezal</surname><given-names>R.</given-names></name><name><surname>Babkova</surname><given-names>K.</given-names></name><name><surname>Horova</surname><given-names>A.</given-names></name><name><surname>Malinak</surname><given-names>D.</given-names></name><name><surname>Mezeiova</surname><given-names>E.</given-names></name><name><surname>Gorecki</surname><given-names>L.</given-names></name><name><surname>Sepsova</surname><given-names>V.</given-names></name><etal/></person-group><article-title>7-Methoxytacrine-<italic>p</italic>-anisidine hybrids as novel dual binding site acetylcholinesterase inhibitors for Alzheimer&#8217;s disease treatment</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>22084</fpage><lpage>22101</lpage><pub-id pub-id-type="doi">10.3390/molecules201219836</pub-id><?supplied-pmid 26690394?><pub-id pub-id-type="pmid">26690394</pub-id></element-citation></ref><ref id="B17-molecules-23-02033"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoury</surname><given-names>R.</given-names></name><name><surname>Patel</surname><given-names>K.</given-names></name><name><surname>Gold</surname><given-names>J.</given-names></name><name><surname>Hinds</surname><given-names>S.</given-names></name><name><surname>Grossberg</surname><given-names>G.T.</given-names></name></person-group><article-title>Recent progress in the pharmacotherapy of Alzheimer&#8217;s disease</article-title><source>Drugs Aging</source><year>2017</year><volume>34</volume><fpage>811</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1007/s40266-017-0499-x</pub-id><?supplied-pmid 29116600?><pub-id pub-id-type="pmid">29116600</pub-id></element-citation></ref><ref id="B18-molecules-23-02033"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korabecny</surname><given-names>J.</given-names></name><name><surname>Musilek</surname><given-names>K.</given-names></name><name><surname>Holas</surname><given-names>O.</given-names></name><name><surname>Nepovimova</surname><given-names>E.</given-names></name><name><surname>Jun</surname><given-names>D.</given-names></name><name><surname>Zemek</surname><given-names>F.</given-names></name><name><surname>Opletalova</surname><given-names>V.</given-names></name><name><surname>Patocka</surname><given-names>J.</given-names></name><name><surname>Dohnal</surname><given-names>V.</given-names></name><name><surname>Nachon</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Synthesis and in vitro evaluation of <italic>N</italic>-(bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer&#8217;s disease treatment</article-title><source>Molecules</source><year>2010</year><volume>15</volume><fpage>8804</fpage><lpage>8812</lpage><pub-id pub-id-type="doi">10.3390/molecules15128804</pub-id><?supplied-pmid 21127466?><pub-id pub-id-type="pmid">21127466</pub-id></element-citation></ref><ref id="B19-molecules-23-02033"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panek</surname><given-names>D.</given-names></name><name><surname>Wi&#281;ckowska</surname><given-names>A.</given-names></name><name><surname>Wichur</surname><given-names>T.</given-names></name><name><surname>Bajda</surname><given-names>M.</given-names></name><name><surname>Gody&#324;</surname><given-names>J.</given-names></name><name><surname>Jo&#324;czyk</surname><given-names>J.</given-names></name><name><surname>Mika</surname><given-names>K.</given-names></name><name><surname>Janockova</surname><given-names>J.</given-names></name><name><surname>Soukup</surname><given-names>O.</given-names></name><name><surname>Knez</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>125</volume><fpage>676</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.09.078</pub-id><?supplied-pmid 27721153?><pub-id pub-id-type="pmid">27721153</pub-id></element-citation></ref><ref id="B20-molecules-23-02033"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.Y.</given-names></name><name><surname>Dai</surname><given-names>Y.C.</given-names></name><name><surname>Li</surname><given-names>N.G.</given-names></name><name><surname>Dong</surname><given-names>Z.X.</given-names></name><name><surname>Gu</surname><given-names>T.</given-names></name><name><surname>Shi</surname><given-names>Z.H.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>Y.P.</given-names></name><name><surname>Duan</surname><given-names>J.A.</given-names></name></person-group><article-title>Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer's disease</article-title><source>J. Enzyme Inhib. Med. Chem.</source><year>2017</year><volume>32</volume><fpage>572</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1080/14756366.2016.1210139</pub-id><?supplied-pmid 28133981?><pub-id pub-id-type="pmid">28133981</pub-id></element-citation></ref><ref id="B21-molecules-23-02033"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spilovska</surname><given-names>K.</given-names></name><name><surname>Korabecny</surname><given-names>J.</given-names></name><name><surname>Sepsova</surname><given-names>V.</given-names></name><name><surname>Jun</surname><given-names>D.</given-names></name><name><surname>Hrabinova</surname><given-names>M.</given-names></name><name><surname>Jost</surname><given-names>P.</given-names></name><name><surname>Muckova</surname><given-names>L.</given-names></name><name><surname>Soukup</surname><given-names>O.</given-names></name><name><surname>Janockova</surname><given-names>J.</given-names></name><name><surname>Kucera</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Novel tacrine-scutellarin hybrids as multipotent anti-Alzheimer&#8217;s agents: Design, synthesis and biological evaluation</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1006</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22061006</pub-id><?supplied-pmid 28621747?><pub-id pub-id-type="pmid">28621747</pub-id></element-citation></ref><ref id="B22-molecules-23-02033"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko&#353;ak</surname><given-names>U.</given-names></name><name><surname>Brus</surname><given-names>B.</given-names></name><name><surname>Knez</surname><given-names>D.</given-names></name><name><surname>&#352;ink</surname><given-names>R.</given-names></name><name><surname>&#381;akelj</surname><given-names>S.</given-names></name><name><surname>Trontelj</surname><given-names>J.</given-names></name><name><surname>Pi&#353;lar</surname><given-names>A.</given-names></name><name><surname>&#352;lenc</surname><given-names>J.</given-names></name><name><surname>Gobec</surname><given-names>M.</given-names></name><name><surname>&#381;ivin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Development of an in vivo active reversible butyrylcholinesterase inhibitor</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>39495</fpage><pub-id pub-id-type="doi">10.1038/srep39495</pub-id><?supplied-pmid 28000737?><pub-id pub-id-type="pmid">28000737</pub-id></element-citation></ref><ref id="B23-molecules-23-02033"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawatzky</surname><given-names>E.</given-names></name><name><surname>Wehle</surname><given-names>S.</given-names></name><name><surname>Kling</surname><given-names>B.</given-names></name><name><surname>Wendrich</surname><given-names>J.</given-names></name><name><surname>Bringmann</surname><given-names>G.</given-names></name><name><surname>Sotriffer</surname><given-names>C.A.</given-names></name><name><surname>Heilmann</surname><given-names>J.</given-names></name><name><surname>Decker</surname><given-names>M.</given-names></name></person-group><article-title>Discovery of highly selective and nanomolar carbamate-based butyrylcholinesterase inhibitors by rational investigation into their inhibition mode</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>2067</fpage><lpage>2082</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01674</pub-id><?supplied-pmid 26886849?><pub-id pub-id-type="pmid">26886849</pub-id></element-citation></ref><ref id="B24-molecules-23-02033"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#225;tk&#253;</surname><given-names>M.</given-names></name><name><surname>&#352;t&#283;p&#225;nkov&#225;</surname><given-names>S.</given-names></name><name><surname>Vor&#269;&#225;kov&#225;</surname><given-names>K.</given-names></name><name><surname>&#352;varcov&#225;</surname><given-names>M.</given-names></name><name><surname>Vinsova</surname><given-names>J.</given-names></name></person-group><article-title>Novel cholinesterase inhibitors based on <italic>o</italic>-aromatic <italic>N</italic>,<italic>N</italic>-disubstituted carbamates and thiocarbamates</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>191</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21020191</pub-id><?supplied-pmid 26875979?><pub-id pub-id-type="pmid">26875979</pub-id></element-citation></ref><ref id="B25-molecules-23-02033"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolet</surname><given-names>Y.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name><name><surname>Masson</surname><given-names>P.</given-names></name><name><surname>Fontecilla-Camps</surname><given-names>J.C.</given-names></name><name><surname>Nachon</surname><given-names>F.</given-names></name></person-group><article-title>Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>41141</fpage><lpage>41147</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210241200</pub-id><?supplied-pmid 12869558?><pub-id pub-id-type="pmid">12869558</pub-id></element-citation></ref><ref id="B26-molecules-23-02033"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucier</surname><given-names>G.W.</given-names></name><name><surname>McDaniel</surname><given-names>O.S.</given-names></name><name><surname>Matthews</surname><given-names>H.B.</given-names></name></person-group><article-title>Microsomal rat liver UDP glucuronyltransferase. Effects of piperonyl butoxide and other factors on enzyme activity</article-title><source>Arch. Biochem. Biophys.</source><year>1971</year><volume>145</volume><fpage>520</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/S0003-9861(71)80012-7</pub-id><pub-id pub-id-type="pmid">5125203</pub-id></element-citation></ref><ref id="B27-molecules-23-02033"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>R.W.</given-names></name></person-group><article-title>Effects of nonpathogenic strains of fusarium oxysporum on celery root infection by <italic>F. oxysporum</italic> f. sp. apii and a novel use of the Limeweaver-Burk double reciprocal plot technique</article-title><source>Phytopathology</source><year>1984</year><volume>74</volume><fpage>646</fpage><pub-id pub-id-type="doi">10.1094/Phyto-74-646</pub-id></element-citation></ref><ref id="B28-molecules-23-02033"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Rocha</surname><given-names>J.B.</given-names></name><name><surname>Correa</surname><given-names>M.</given-names></name><name><surname>Mazzanti</surname><given-names>C.M.</given-names></name><name><surname>Zanin</surname><given-names>R.F.</given-names></name><name><surname>Morsch</surname><given-names>A.L.</given-names></name><name><surname>Morsch</surname><given-names>V.M.</given-names></name><name><surname>Schetinger</surname><given-names>M.R.</given-names></name></person-group><article-title>Inhibition of two different cholinesterases by tacrine</article-title><source>Chem. Biol. Interact.</source><year>2006</year><volume>162</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.cbi.2006.06.002</pub-id><?supplied-pmid 16860785?><pub-id pub-id-type="pmid">16860785</pub-id></element-citation></ref><ref id="B29-molecules-23-02033"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Mai</surname><given-names>Y.C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hou</surname><given-names>J.Q.</given-names></name><name><surname>Huang</surname><given-names>S.L.</given-names></name><name><surname>Ou</surname><given-names>T.M.</given-names></name><name><surname>Tan</surname><given-names>J.H.</given-names></name><name><surname>An</surname><given-names>L.K.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Gu</surname><given-names>L.Q.</given-names></name><etal/></person-group><article-title>Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors</article-title><source>Eur. J. Med. Chem.</source><year>2010</year><volume>45</volume><fpage>1415</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2009.12.044</pub-id><?supplied-pmid 20079560?><pub-id pub-id-type="pmid">20079560</pub-id></element-citation></ref><ref id="B30-molecules-23-02033"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Mu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name></person-group><article-title>Graveoline analogs exhibiting selective acetylcholinesterase inhibitory activity as potential lead compounds for the treatment of alzheimer&#8217;s disease</article-title><source>Molecules</source><year>2016</year><volume>21</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.3390/molecules21020132</pub-id><?supplied-pmid 26805806?><pub-id pub-id-type="pmid">26805806</pub-id></element-citation></ref><ref id="B31-molecules-23-02033"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachon</surname><given-names>F.</given-names></name><name><surname>Carletti</surname><given-names>E.</given-names></name><name><surname>Ronco</surname><given-names>C.</given-names></name><name><surname>Trovaslet</surname><given-names>M.</given-names></name><name><surname>Nicolet</surname><given-names>Y.</given-names></name><name><surname>Jean</surname><given-names>L.</given-names></name><name><surname>Renard</surname><given-names>P.Y.</given-names></name></person-group><article-title>Crystal structures of human cholinesterases in complex with huprine W and tacrine: Elements of specificity for anti-Alzheimer&#8217;s drugs targeting acetyl- and butyryl-cholinesterase</article-title><source>Biochem. J.</source><year>2013</year><volume>453</volume><fpage>393</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1042/BJ20130013</pub-id><?supplied-pmid 23679855?><pub-id pub-id-type="pmid">23679855</pub-id></element-citation></ref><ref id="B32-molecules-23-02033"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>J.T.</given-names></name><name><surname>Clark</surname><given-names>D.E.</given-names></name></person-group><article-title>In Silico Predictions of Blood-Brain Barrier Penetration: Considerations to &#8220;Keep in Mind&#8221;</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2005</year><volume>315</volume><fpage>477</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.075705</pub-id><?supplied-pmid 15919767?><pub-id pub-id-type="pmid">15919767</pub-id></element-citation></ref><ref id="B33-molecules-23-02033"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Bhatia</surname><given-names>P.A.</given-names></name><name><surname>Daanen</surname><given-names>J.F.</given-names></name><name><surname>Latsaw</surname><given-names>S.P.</given-names></name><name><surname>Rohde</surname><given-names>J.</given-names></name><name><surname>Kolasa</surname><given-names>T.</given-names></name><name><surname>Hakeem</surname><given-names>A.A.</given-names></name><name><surname>Matulenko</surname><given-names>M.A.</given-names></name><name><surname>Nakane</surname><given-names>M.</given-names></name><name><surname>Uchic</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Synthesis and evaluation of 3-aryl piperidine analogs as potent and efficacious dopamine D4 receptor agonists</article-title><source>Bioorg. Med. Chem.</source><year>2005</year><volume>13</volume><fpage>4667</fpage><lpage>4678</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2005.04.060</pub-id><?supplied-pmid 15896964?><pub-id pub-id-type="pmid">15896964</pub-id></element-citation></ref><ref id="B34-molecules-23-02033"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demir-&#214;zkay</surname><given-names>U.</given-names></name><name><surname>&#214;zkay</surname><given-names>Y.</given-names></name><name><surname>Can</surname><given-names>&#214;.</given-names></name></person-group><article-title>Synthesis and analgesic effects of 2-(2-carboxyphenylsulfanyl)-<italic>N</italic>-(4-substitutedphenyl)acetamide derivatives</article-title><source>Med. Chem. Res.</source><year>2011</year><volume>20</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/s00044-010-9300-y</pub-id></element-citation></ref><ref id="B35-molecules-23-02033"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellman</surname><given-names>G.L.</given-names></name><name><surname>Courtney</surname><given-names>K.D.</given-names></name><name><surname>Andres</surname><given-names>V.J.</given-names></name><name><surname>Feather-Stone</surname><given-names>R.M.</given-names></name></person-group><article-title>A new and rapid colorimetric determination of acetylcholinesterase activity</article-title><source>Biochem. Pharmacol.</source><year>1961</year><volume>7</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(61)90145-9</pub-id><pub-id pub-id-type="pmid">13726518</pub-id></element-citation></ref><ref id="B36-molecules-23-02033"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yurtta&#351;</surname><given-names>L.</given-names></name><name><surname>Kaplanc&#305;kl&#305;</surname><given-names>Z.A.</given-names></name><name><surname>Ozkay</surname><given-names>Y.</given-names></name></person-group><article-title>Design, synthesis and evaluation of new thiazole-piperazines as acetylcholinesterase inhibitors</article-title><source>J. Enzyme Inhib. Med. Chem.</source><year>2013</year><volume>28</volume><fpage>1040</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.3109/14756366.2012.709242</pub-id><?supplied-pmid 22871134?><pub-id pub-id-type="pmid">22871134</pub-id></element-citation></ref><ref id="B37-molecules-23-02033"><label>37.</label><element-citation publication-type="book"><source>Maestro</source><comment>version 10.6</comment><publisher-name>Schr&#246;dinger, LLC</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B38-molecules-23-02033"><label>38.</label><element-citation publication-type="book"><source>Schr&#246;dinger</source><comment>version 2016-2</comment><publisher-name>Schr&#246;dinger, LLC</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B39-molecules-23-02033"><label>39.</label><element-citation publication-type="book"><source>LigPrep</source><comment>version 3.8</comment><publisher-name>Schr&#246;dinger, LLC</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B40-molecules-23-02033"><label>40.</label><element-citation publication-type="book"><source>Glide</source><comment>version 7.1</comment><publisher-name>Schr&#246;dinger, LLC</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2016</year></element-citation></ref><ref id="B41-molecules-23-02033"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berridge</surname><given-names>M.V.</given-names></name><name><surname>Herst</surname><given-names>P.M.</given-names></name><name><surname>Tan</surname><given-names>A.S.</given-names></name></person-group><article-title>Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction</article-title><source>Biotechnol. Annu. Rev.</source><year>2005</year><volume>11</volume><fpage>127</fpage><lpage>152</lpage><?supplied-pmid 16216776?><pub-id pub-id-type="pmid">16216776</pub-id></element-citation></ref><ref id="B42-molecules-23-02033"><label>42.</label><element-citation publication-type="web"><article-title>The Blood-Brain Barrier (BBB) Prediction Server&#8212;CBLigand</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.cbligand.org/BBB/index.php">http://www.cbligand.org/BBB/index.php</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-02-27">(accessed on 27 February 2017)</date-in-citation></element-citation></ref><ref id="B43-molecules-23-02033"><label>43.</label><element-citation publication-type="web"><article-title>Drug-Likeness and Molecular Property Prediction</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://molsoft.com/mprop/">http://molsoft.com/mprop/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-03-02">(accessed on 2 March 2017)</date-in-citation></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><fig id="molecules-23-02033-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Design strategy of recently synthesized derivatives.</p></caption><graphic xlink:href="molecules-23-02033-g001"/></fig><fig id="molecules-23-02033-sch001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-23-02033-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of compounds <bold>4a</bold>&#8211;<bold>4u</bold>. (<bold>a</bold>): (C<sub>2</sub>H<sub>5</sub>)<sub>3</sub>N/THF/0 &#176;C then rt; (<bold>b</bold>) acetone/reflux.</p></caption><graphic xlink:href="molecules-23-02033-sch001"/><table-wrap id="molecules-23-02033-t011" orientation="portrait" position="anchor"/></fig><fig id="molecules-23-02033-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Lineweaver&#8211;Burk plot for the inhibition of human butyrylcholinesterase (BChE) by compound <bold>4n</bold> at different concentrations of substrate butyrylthiocholine iodide (BTCI).</p></caption><graphic xlink:href="molecules-23-02033-g002"/></fig><fig id="molecules-23-02033-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Secondary plot for calculation of the steady-state inhibition constant (K<sub>i</sub> = 0.0175 &#181;M against BChE) of compound <bold>4n</bold>.</p></caption><graphic xlink:href="molecules-23-02033-g003"/></fig><fig id="molecules-23-02033-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Two-dimensional interaction of compound <bold>4n</bold> with BChE.</p></caption><graphic xlink:href="molecules-23-02033-g004"/></fig><fig id="molecules-23-02033-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Three-dimensional interaction of compound <bold>4n</bold> with BChE.</p></caption><graphic xlink:href="molecules-23-02033-g005"/></fig><table-wrap id="molecules-23-02033-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-23-02033-t001_Table 1</object-id><label>Table 1</label><caption><p>Inhibitory activity (%) of compounds <bold>4a</bold>&#8211;<bold>4u</bold> against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes at 10<sup>&#8722;4</sup> M concentration and their half maximal inhibitory concentration (IC<sub>50</sub>; &#181;M) values against these enzymes.</p></caption><table-wrap-foot><fn><p>* Represents the selected compounds for second step due to more than 50% inhibitory potency at 10<sup>&#8722;4</sup> M concentration.</p></fn></table-wrap-foot></table-wrap><table-wrap id="molecules-23-02033-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-23-02033-t002_Table 2</object-id><label>Table 2</label><caption><p>IC<sub>50</sub> of selected derivatives against a murine fibroblast healthy cell line (NIH3T3).</p></caption></table-wrap><table-wrap id="molecules-23-02033-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-23-02033-t003_Table 3</object-id><label>Table 3</label><caption><p>Drug-likeness score (DLS) and blood&#8211;brain barrier (BBB) permeability of the active compounds.</p></caption></table-wrap></sec></back></article>